Paper33671024
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.
Hulmi JJ and 3 others. Cells, 2021. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments. Papers, record 33671024. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33671024
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Activin Receptors, Type II | Major topic |
| Cachexia | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Signal Transduction | |
| Survival Analysis |
Source PubMed
References230
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30833900 | The Skeletal Muscle as an Active Player Against Cancer Cachexia. | Front Physiol | 2019 | https://conductscience.org/library/papers/30833900 | PubMed |
| 2 | 21677277 | Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. | Am J Physiol Regul Integr Comp Physiol | 2011 | https://conductscience.org/library/papers/21677277 | PubMed |
| 3 | 30156376 | Low skeletal muscle mass in stented esophageal cancer predicts poor survival: A retrospective observational study. | Thorac Cancer | 2018 | https://conductscience.org/library/papers/30156376 | PubMed |
| 4 | 25460504 | Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. | Oncotarget | 2015 | https://conductscience.org/library/papers/25460504 | PubMed |
| 5 | 23966665 | Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. | J Lipid Res | 2013 | https://conductscience.org/library/papers/23966665 | PubMed |
| 6 | 24333131 | A myostatin and activin decoy receptor enhances bone formation in mice. | Bone | 2014 | https://conductscience.org/library/papers/24333131 | PubMed |
| 7 | 19779154 | Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. | J Appl Physiol (1985) | 2009 | https://conductscience.org/library/papers/19779154 | PubMed |
| 8 | 9288100 | A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. | Nat Genet | 1997 | https://conductscience.org/library/papers/9288100 | PubMed |
| 9 | 20810712 | Regulation of muscle mass by follistatin and activins. | Mol Endocrinol | 2010 | https://conductscience.org/library/papers/20810712 | PubMed |
| 10 | 31177056 | Mediators of cachexia in cancer patients. | Nutrition | 2019 | https://conductscience.org/library/papers/31177056 | PubMed |
| 11 | 29089584 | ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. | Sci Rep | 2017 | https://conductscience.org/library/papers/29089584 | PubMed |
| 12 | 25336187 | Myostatin gene inactivation prevents skeletal muscle wasting in cancer. | Cancer Res | 2014 | https://conductscience.org/library/papers/25336187 | PubMed |
| 13 | 26453500 | Bone and muscle: Interactions beyond mechanical. | Bone | 2015 | https://conductscience.org/library/papers/26453500 | PubMed |
| 14 | 31322699 | Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. | Endocrinology | 2019 | https://conductscience.org/library/papers/31322699 | PubMed |
| 15 | 33408083 | A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities. | Dis Model Mech | 2021 | https://conductscience.org/library/papers/33408083 | PubMed |
| 16 | 9139826 | Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. | Nature | 1997 | https://conductscience.org/library/papers/9139826 | PubMed |
| 17 | 25399825 | Development of novel activin-targeted therapeutics. | Mol Ther | 2015 | https://conductscience.org/library/papers/25399825 | PubMed |
| 18 | 27807421 | Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. | Front Physiol | 2016 | https://conductscience.org/library/papers/27807421 | PubMed |
| 19 | 32673155 | Making Mice Mighty: recent advances in translational models of load-induced muscle hypertrophy. | J Appl Physiol (1985) | 2020 | https://conductscience.org/library/papers/32673155 | PubMed |
| 20 | 24861054 | Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. | Mol Ther | 2014 | https://conductscience.org/library/papers/24861054 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40943156 | Relationship Between High Serum Levels of Follistatin with Impaired Physical Function, and Severe Disease Activity in Rheumatoid Arthritis. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943156 | PubMed |
| 40419762 | Skeletal muscle endothelial dysfunction through the activin A-PGC1α axis drives progression of cancer cachexia. | Nat Cancer | 2025 | https://conductscience.org/library/papers/40419762 | PubMed |
| 39636147 | Diversity in chemotherapy-induced cachexia. | Am J Physiol Cell Physiol | 2025 | https://conductscience.org/library/papers/39636147 | PubMed |
| 39253924 | Activin A-Targeted Therapy in Cancer: An Updated Review on Challenges and Opportunities in Clinical Translation. | Curr Pharm Des | 2026 | https://conductscience.org/library/papers/39253924 | PubMed |
| 38392348 | The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance. | Biology (Basel) | 2024 | https://conductscience.org/library/papers/38392348 | PubMed |
| 36834742 | Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36834742 | PubMed |
| 36078078 | Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics. | Cells | 2022 | https://conductscience.org/library/papers/36078078 | PubMed |
| 35941104 | Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer. | Nat Commun | 2022 | https://conductscience.org/library/papers/35941104 | PubMed |
| 35812316 | Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies. | Front Physiol | 2022 | https://conductscience.org/library/papers/35812316 | PubMed |
| 35580932 | Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35580932 | PubMed |
| 35326441 | Cardiac Cachexia: Unaddressed Aspect in Cancer Patients. | Cells | 2022 | https://conductscience.org/library/papers/35326441 | PubMed |
| 35190301 | Emerging signaling mediators in the anorexia-cachexia syndrome of cancer. | Trends Cancer | 2022 | https://conductscience.org/library/papers/35190301 | PubMed |
| 34548663 | Tumours block protective muscle and nerve signals to cause cachexia. | Nature | 2021 | https://conductscience.org/library/papers/34548663 | PubMed |
| 34298829 | Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34298829 | PubMed |
Genes23
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33671024
GET https://conductscience.org/api/papers/v1/33671024/references?page=2